XML 70 R54.htm IDEA: XBRL DOCUMENT

Operating Segments (Tables)

12 Months Ended

Dec. 31, 2022

Operating Segments [Abstract]

Schedule of Operating Segments

		Year ended December 31, 2022
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	1,347			$	1,347
Inter-segment			-				-				-
Total			-				1,347				1,347

Segment loss (gain)			8,405				(118	)			8,287
Company’s share of losses of company accounted for at equity, net											109
Finance expense (income), net											(5,818	)
Tax expense											14

Loss											2,592

		Year ended December 31, 2021
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	-			$	-
Inter-segment			-				-				-
Total			-				-				-

Segment loss			5,768				-				5,768
Finance expense (income), net											21

Loss											5,789

		Year ended December 31, 2020
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	-			$	-
Inter-segment			-				-				-
Total			-				-				-

Segment loss			3,293				-				3,293
Finance expense (income), net											242

Loss											3,535

		As of December 31, 2022
		Drug Development				Online Sales				Total

Segment Assets		$	9,664			$	941			$	10,605
Segment Liabilities		$	4,021			$	135			$	4,156

		As of December 31, 2021
		Drug Development				Online Sales				Total

Segment Assets		$	9,916			$	-			$	9,916
Segment Liabilities		$	1,775			$	-			$	1,775